Healthcare AI is developing at a rapid rate, and the industry’s attitude on how to best regulate and deploy this technology is evolving every day, according to leaders attending this year’s ViVE conference. The post ‘The Hardest Thing Is Separating the Wheat from the Chaff’: 5 Leaders on the State of Healthcare AI appeared first…
Compounded GLP-1s have become more widespread, but are they safe? Some argue that compounding is nothing new, while others believe these drugs are dangerous for patients. The post Hims & Hers vs. Novo Nordisk: Are Compounded GLP-1s Safe? appeared first on MedCity News.
BridgeBio Pharma’s approval of Beyonttra comes three months after the drug landed FDA approval for cardiomyopathy caused by transthyretin amyloidosis. Our recap of recent regulatory news also spans approvals in cancer, immunology, vaccines, and more. The post On Heels of FDA Nod, BridgeBio’s Rival to Blockbuster Pfizer Drug Wins European Approval appeared first on MedCity…
The distinction between value-based care and value-based payment isn’t merely semantic — it represents a crucial fork in the road for healthcare delivery. As AI and other technologies become more prevalent in healthcare, we must ensure they’re deployed in service of improving patient care rather than merely optimizing revenue. The post The Dark Side of…
For too long, the behavioral health industry has lacked the accountability mechanisms required to deliver on the high quality care that patients deserve. Provider organizations are proving day in, day out that when strong accountability becomes the standard, patients benefit, and the system as a whole grows stronger. The post It’s Time for Health Plans…
KFF Health News editor-at-large for public health Céline Gounder discussed the possibility of a bird flu pandemic on WAMU’s “1A” on Feb. 20. Gounder also discussed the potential of an off-label drug being studied to help some autistic kids improve their ability to speak on CBS News’ “CBS Evening News” on Feb. 17. Click here…
A paper by Proudman et al. (2024) finds that doing so would be extremely expensive. Including all preclinical, clinical and post-approval R&D activities, total annual costs to maintain the average lifecycle level of 49.4 approved drugs across all disease areas during the 2018–22 period was estimated to be $139.6 billion. Including only pre-launch costs, total…
Carlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird Bio for about $29 million. Meanwhile, Pfizer continued the culling of its gene therapies with the discontinuation of Beqvez for hemophilia B. The post Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees to Acquisition by Private Equity appeared first on MedCity News.
Hospitals are adopting AI technology more than ever before, but they still face challenges when it comes to measuring the impact of these solutions and scaling them, noted Kiran Mysore, chief data & analytics officer at Sutter Health. The post Hospitals Are Adopting AI — But Can They Measure and Scale These Tools? appeared first…
This fact sheet provides an overview of the history of the Kemp-Kasten amendment, which states that no U.S. funds may be made available to “any organization or program which, as determined by the president of the United States, supports or participates in the management of a program of coercive abortion or involuntary sterilization,” and examines…